Trial Profile
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fimasartan (Primary) ; Rosuvastatin
- Indications Dyslipidaemias; Essential hypertension
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 30 Jun 2016 Status changed from not yet recruiting to completed.
- 20 Jun 2014 New trial record